Skip to main content
SpringerLink
Log in

Autoimmunerkrankungen

  • Chapter
NeuroIntensiv

  • 1432 Accesses

Auszug

Die Sarkoidose ist eine multisystemische granulomatöse Autoimmunerkrankung unbekannter Ätiologie. Beobachtet wird eine gehäufte Assoziation mit bestimmten HLA-Genen (HLA-B8, HLA-DR17). Aufgrund der Immunreaktionen in den Frühphasen der Erkrankung vermutet man, dass bei einer entsprechenden genetischen Disposition infektiöse und nichtinfektiöse antigene Umgebungsfaktoren in den Zielorganen zu Aktivierung und Expansion von T-Zellen, insbesondere TH1-Zellen führt, die die Immunreaktion initiieren.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. ATS Board of Directors and by the ERS Executive Committee. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG). February 1999. Am J Respir Crit Care Med. 1999 Aug; 160(2):736–55.

    Google Scholar 

  2. Barnard J, Newman LS. Sarcoidosis: immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol. 2001 Jan; 13(1): 84–91.

    Article  PubMed  CAS  Google Scholar 

  3. Berger C, Sommer C, Meinck HM. Isolated sarcoid myopathy. Muscle Nerve. 2002 Oct;26(4):553–6.

    Article  PubMed  Google Scholar 

  4. Bunting PS, Szalai JP, Katic M. Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis. Clin Biochem. 1987 Jun; 20(3): 213–9.

    Article  PubMed  CAS  Google Scholar 

  5. Christoforidis GA, Spickler EM, Recio MV, Mehta BM. MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. AJNR Am J Neuroradiol. 1999 Apr; 20(4): 655–69.

    PubMed  CAS  Google Scholar 

  6. Hayat GR, Walton TP, Smith KR Jr, Martin DS, Manepalli AN. Solitary intramedullary neurosarcoidosis: role of MRI in early detection. J Neuroimaging. 2001 Jan; 11(1): 66–70.

    Article  PubMed  CAS  Google Scholar 

  7. Hershcovici T, Mekhmandorov S, Beigel Y, Hardoff R. The value of Ga-67 scintigraphy in sarcoid myopathy. Clin Nucl Med. 2001 Jun; 26(6): 540–2

    Article  PubMed  CAS  Google Scholar 

  8. Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol. 2004 Jul; 3(7): 397–407

    Article  PubMed  Google Scholar 

  9. Kramers C, Deinum J. Increased serum activity of angiotensin-converting enzyme (ACE): indication of sarcoidosis? A ‘Bayesian’ approach] Ned Tijdschr Geneeskd. 2003 Mar 15; 147(11): 473–6

    PubMed  CAS  Google Scholar 

  10. Leclerc S, Myers RP, Moussalli J, Herson S, Poynard T, Benveniste O. Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur J Intern Med. 2003 Jul; 14(4): 237–243.

    Article  PubMed  CAS  Google Scholar 

  11. Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol. 2001 May; 248(5): 363–72.

    Article  PubMed  CAS  Google Scholar 

  12. Reske D, Petereit HF, Heiss WD. Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system — value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand. 2005; 112: 207–213

    Article  PubMed  CAS  Google Scholar 

  13. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest. 2003 Nov; 124(5): 2028–31.

    Article  PubMed  Google Scholar 

  14. Sohn HS, Kim EN, Park JM, Chung YA. Muscular sarcoidosis: Ga-67 scintigraphy and magnetic resonance imaging. Clin Nucl Med. 2001 Jan; 26(1): 29–32

    Article  PubMed  CAS  Google Scholar 

  15. Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum. 2003 Dec; 48(12): 3542–3

    Article  PubMed  Google Scholar 

  16. Walter MC, Lochmuller H, Schlotter-Weigel B, Meindl T, Muller-Felber W. Successful treatment of muscle sarcoidosis with thalidomide. Acta Myol. 2003 May; 22(1): 22–5.

    PubMed  CAS  Google Scholar 

  17. Woitalla D, Henkes H, Felber S, Weber W, Janisch W, Kuhne D. Clinical aspects and diagnostic imaging in sarcoidosis of the nervous system. Radiologe. 2000 Nov; 40(11): 1064–76.

    Article  PubMed  CAS  Google Scholar 

  18. Zettl UK, Lehmitz R, Mix E. Klinische Liquordiagnostik. Berlin, New York: Walter de Gruyter 2003

    Google Scholar 

Literatur

  1. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus. Arthritis Rheum 1999; 42: 599–608.

    Article  Google Scholar 

  2. Berlit P: Vaskulitis. In: Hamann GF, Siebler M, von Scheidt W (Eds). Schlaganfall. Ecomed Landsberg 2002: 244–267

    Google Scholar 

  3. Berlit P, Steinbrecher A. Zerebrale Vaskulitis. Fortschr Neurol Psych 2002; 70: 663–677

    Article  CAS  Google Scholar 

  4. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156–62.

    Article  PubMed  CAS  Google Scholar 

  5. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248–57.

    PubMed  CAS  Google Scholar 

  6. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002; 46: 1003–1013.

    Article  PubMed  CAS  Google Scholar 

  7. Moore P, Richardson B. Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiat 1998; 65: 10–22

    Article  PubMed  CAS  Google Scholar 

  8. Morton SJ, Powell RJ. Management of systemic lupus erythematosus (SLE). Clin Exp Allergy 2001; 31: 686–93.

    Article  PubMed  CAS  Google Scholar 

  9. Mosca M, Ruiz-Irastorza G, Khamashta MA, Hughes GR. Treatment of systemic lupus erythematosus. Int Immunopharmacol 2001; 1: 1065–75.

    Article  PubMed  CAS  Google Scholar 

  10. Ortmann RA, Klippel JH. Update on cyclophosphamide for systemic lupus erythematosus. Rheum Dis Clin North Am 2000; 26: 363–75, vii.

    Article  PubMed  CAS  Google Scholar 

  11. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet 2001; 357: 1027–32.

    Article  PubMed  CAS  Google Scholar 

  12. Sibbitt WL, Jr., Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2026–38.

    Article  PubMed  Google Scholar 

  13. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10: 154–61.

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Apak RA, Anlar B, Saatci I. A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev. 1999 Jun; 21(4): 279–82.

    Article  PubMed  CAS  Google Scholar 

  2. Bizzi A, Ulug AM, Crawford TO, Passe T, Bugiani M, Bryan RN, Barker PB. Quantitative proton MR spectroscopic imaging in acute disseminated encephalomyelitis. AJNR Am J Neuroradiol. 2001 Jun–Jul; 22(6): 1125–30

    PubMed  CAS  Google Scholar 

  3. Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000 Dec; 123 Pt 12: 2407–22.

    Article  PubMed  Google Scholar 

  4. Finsterer J, Grass R, Stollberger C, Mamoli B. Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis. Clin Neuropharmacol. 1998 Jul–Aug; 21(4): 258–61

    PubMed  CAS  Google Scholar 

  5. Gupte G, Stonehouse M, Wassmer E, Coad NA, Whitehouse WP. Acute disseminated encephalomyelitis: a review of 18 cases in childhood. J Paediatr Child Health. 2003 Jul; 39(5): 336–42

    Article  PubMed  CAS  Google Scholar 

  6. Haase CG, Faustmann PM, Diener H. Idiopathic inflammatory demyelinating diseases of the central nervous system: differentiating between acute disseminated encephalomyelitis and malignant multiple sclerosis. J Clin Neurosci. 1999 May; 6(3): 221–226.

    Article  PubMed  Google Scholar 

  7. Hahn CD, Miles BS, MacGregor DL, Blaser SI, Banwell BL, Hetherington CR. Neurocognitive outcome after acute disseminated encephalomyelitis. Pediatr Neurol. 2003 Aug; 29(2): 117–23.

    Article  PubMed  Google Scholar 

  8. Hart MN, Earle KM. Haemorrhagic and perivenous encephalitis: a clinical-pathological review of 38 cases. J Neurol Neurosurg Psychiatry. 1975 Jun; 38(6): 585–91.

    Article  PubMed  CAS  Google Scholar 

  9. Hurst EW. Acute haemorrhagic leuco-encephalitis, a previuosly undefined entity. Medical Journal of Australia. 1941, 2: 1–6

    Google Scholar 

  10. Inglese M, Salvi F, Iannucci G, Mancardi GL, Mascalchi M, Filippi M. Magnetization transfer and diffusion tensor MR imaging of acute disseminated encephalomyelitis. AJNR Am J Neuroradiol. 2002 Feb; 23(2): 267–72

    PubMed  Google Scholar 

  11. Ichiyama T, Shoji H, Kato M. Cerebrospinal fluid levels of cytokines and soluble tumour necrosis factor receptor in acute disseminated encephalomyelitis. Eur J Pediatr. 2002; 161: 133–137

    Article  PubMed  CAS  Google Scholar 

  12. Krupp LB, Banwell B, Tenembaum S, for the International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related childhood disorders. Neurology 2007 Apr; 68(suppl 2): S7–S12)

    Article  PubMed  Google Scholar 

  13. Kanter DS, Horensky D, Sperling RA, Kaplan JD, Malachowski ME, Churchill WH Jr. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Neurology. 1995 Apr; 45(4): 824–7.

    PubMed  CAS  Google Scholar 

  14. Markus R, Brew BJ, Turner J, Pell M. Successful outcome with aggressive treatment of acute haemorrhagic leukoencephalitis. J Neurol Neurosurg Psychiatry. 1997 Oct; 63(4): 551

    Article  PubMed  CAS  Google Scholar 

  15. Niedermayer I, Deinzer M, Moringlane JR, Feiden W. Neuropathological and neuroradiological aspects of acute disseminated encephalomyelitis (ADEM)] Radiologe. 2000 Nov; 40(11): 1030–5

    Article  PubMed  CAS  Google Scholar 

  16. Pasternak JF, De Vivo DC, Prensky AL. Steroid-responsive encephalomyelitis in childhood. Neurology. 1980 May; 30(5): 481–6.

    PubMed  CAS  Google Scholar 

  17. Pfausler B, Engelhardt K, Kampfl A, Spiss H, Taferner E, Schmutzhard E. Post-infectious central and peripheral nervous system diseases complicating Mycoplasma pneumoniae infection. Report of three cases and review of the literature. Eur J Neurol. 2002 Jan; 9(1): 93–6.

    Article  PubMed  CAS  Google Scholar 

  18. Poser S, Luer W, Bruhn H, Frahm J, Bruck Y, Felgenhauer K. Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand. 1992 Dec; 86(6): 579–85

    Article  PubMed  CAS  Google Scholar 

  19. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients.. Neurology. 2001 May 22; 56(10): 1313–8

    PubMed  CAS  Google Scholar 

  20. Schwarz S, Knauth M, Mohr A, Wildemann B, Sommer C, Storch-Hagenlocher B. Acute disseminated encephalomyelitis (ADEM) Nervenarzt. 2001 Apr; 72(4): 241–54.

    Article  PubMed  CAS  Google Scholar 

  21. Singh S, Alexander M, Korah IP. Acute disseminated encephalomyelitis: MR imaging features. AJR Am J Roentgenol. 1999 Oct; 173(4): 1101–7

    PubMed  CAS  Google Scholar 

  22. Sugita K, Suzuki N, Shimizu N, Takanashi J, Ishii M, Niimi N. Involvement of cytokines in N-methyl-N′-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. Eur Neurol. 1993; 33(5): 358–62.

    Article  PubMed  CAS  Google Scholar 

  23. Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology. 2002 Oct 22; 59(8): 1224–31.

    PubMed  Google Scholar 

  24. Tenembaum S, Chitnis T, Ness J, Hahn JS for the International Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology. 2007 Apr; 68(suppl 2): S23–S36)

    Article  PubMed  Google Scholar 

  25. van der Knaap MS, Valk J. Magnetic resonance of myelin, myelination, and myelin disorders. 2nd edition. Berlin, Heidelberg, New York: Springer 1995

    Google Scholar 

  26. Zettl UK, Lehmitz R, Mix E. Klinische Liquordiagnostik. Berlin, New York: Walter de Gruyter 2003

    Google Scholar 

Literatur

  1. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet’s disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 1999; 122: 2171–82.

    Article  PubMed  Google Scholar 

  2. Berlit P. The spectrum of vasculopathies in the differential diagnosis of vasculitis. Sem Neurol 1994; 14: 370–379.

    Article  CAS  Google Scholar 

  3. Berlit P., Steinbrecher A. Zerebrale Vaskulitis. Fortschr Neurol Psych 2002; 70: 663–677

    Article  CAS  Google Scholar 

  4. Calabrese LH, Gragg LA, Furlan AJ Benign angiopathy. A distinct subset of angiographically defined primary angiitis of the CNS. J Rheumatol 1993; 20: 2046–2050

    PubMed  CAS  Google Scholar 

  5. Calabrese LH, Duna GF, Lie JT. Vasculitis in the central nervous system. Arthritis Rheum 1997; 40: 1189–1201

    PubMed  CAS  Google Scholar 

  6. de Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener’s granulomatosis with low dose methotrexate. J Rheumatol 1998; 25: 492–5.

    PubMed  Google Scholar 

  7. de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener’s granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39: 2052–61.

    Article  PubMed  Google Scholar 

  8. de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001; 58: 1215–21.

    Article  PubMed  Google Scholar 

  9. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76–85.

    PubMed  CAS  Google Scholar 

  10. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P. Long-term follow up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666–75.

    Article  PubMed  CAS  Google Scholar 

  11. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 1997; 40: 2187–98.

    Article  PubMed  CAS  Google Scholar 

  12. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74: 238–53.

    Article  PubMed  CAS  Google Scholar 

  13. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, Thibult N, Casassus P: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine-Baltimore 75; 1996: 17–28

    Article  PubMed  CAS  Google Scholar 

  14. Goldberg JW. Primary angiitis of the central nervous system. In Rolak LA, Harati Y (eds). Neuroimmunology for the Clinician. Butterworth-Heinemann. 1997: 177–186

    Google Scholar 

  15. Goodwin J. Temporal arteriitis. In Gilman S. (editor in chief) Neurobase, fourth 2000 edition, Ann Arbor Publishing. 2000

    Google Scholar 

  16. Guillevin L, Lhote F, Sauvaget F, Deblois P, Rossi F, Levallois D, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53: 334–7

    Article  PubMed  CAS  Google Scholar 

  17. Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998; 41: 1835–44

    Article  PubMed  CAS  Google Scholar 

  18. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU (Infl iximab-GCA Study Group). Ann Intern Med 2007; 146: 621–630

    PubMed  Google Scholar 

  19. Irani DN. Neurologic complications of the hepatitis virus. In Gilman S. (editor in chief) Neurobase, fourth 2000 edition, Ann Arbor Publishing. 2000

    Google Scholar 

  20. Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behcet’s syndrome. Brain 1999; 122: 2183–94

    Article  PubMed  Google Scholar 

  21. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener’s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666–73

    Article  PubMed  CAS  Google Scholar 

  22. McRae D, Buchanan G. Long-term sulfamethoxazole-trimethoprim in Wegener’s granulomatosis. Arch Otolaryngol Head Neck Surg 1993; 119: 103–5

    PubMed  CAS  Google Scholar 

  23. Moore PM. Diagnosis and management of isolated angiitis of the central nervous system. Neurology 1989; 39: 167–173

    PubMed  CAS  Google Scholar 

  24. Moore PM, Richardson B. Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiat 1998; 65: 10–22

    Article  PubMed  CAS  Google Scholar 

  25. Murphy JM, Gomez-Anson B, Gillard JH. Wegener Granulomatosis: MR Imaging findings in brain and meninges. Radiology 1999; 213: 794–799

    PubMed  CAS  Google Scholar 

  26. Newman GC. CNS Vasculitis. Clinical neuroimmunology, Education Syllabus, AAN 1998, pp. 2FC.005-143–2FC.005-174

    Google Scholar 

  27. Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993 Jan; 33(1): 4–9

    Article  PubMed  CAS  Google Scholar 

  28. Pomper MG, Miller TJ, Stone JH. CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. AJNR 1999; 20: 75–85

    PubMed  CAS  Google Scholar 

  29. Provenzale JM, Allen NB. Wegener granulomatosis: CT and MR findings. ANJR 1996; 17: 785–792

    CAS  Google Scholar 

  30. Reinhold-Keller E, De Groot K, Rudert H, Nolle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener’s granulomatosis depends on the phase of disease. QJM 1996; 89: 15–23

    PubMed  CAS  Google Scholar 

  31. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med 1999; 341: 1284–91

    Article  PubMed  CAS  Google Scholar 

  32. Schmidley JW. Central nervous system angiitis. Boston: Butterworth-Heinemann 2000

    Google Scholar 

  33. Siva A, Fresko II. Behcet’s Disease. Curr Treat Options Neurol 2000; 2: 435–448

    Article  PubMed  Google Scholar 

  34. Siva A. Vasculitis of the nervous system. J Neurol 2001; 248: 451–468

    Article  PubMed  CAS  Google Scholar 

  35. Specks U, Moder KG, McDonald TJ. Meningeal involvement in Wegener granulomatosis. Mayo Clin Proc 2000; 75: 856–9

    Article  PubMed  CAS  Google Scholar 

  36. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19: 495–501

    PubMed  CAS  Google Scholar 

  37. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335: 16–20

    Article  PubMed  CAS  Google Scholar 

  38. Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26: 1134–9

    PubMed  CAS  Google Scholar 

  39. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124: 477–84

    PubMed  CAS  Google Scholar 

  40. Valeriano-Marcet J, Spiera H. Treatment of Wegener’s granulomatosis with sulfamethoxazole-trimethoprim. Arch Intern Med 1991; 151: 1649–52

    Article  PubMed  CAS  Google Scholar 

  41. Wechsler B, Dell’Isola B, Vidailhet M, Dormont D, Piette JC, Bletry O, Godeau P. MRI in 31 patients with Behcet’s disease and neurological involvement. Prospective study with clinical correlation. J. Neurol Neurosurg Psychiat 1993;56:793–798

    Article  PubMed  CAS  Google Scholar 

  42. Woolfenden AR, Tong DC, Marks MP et al (1998) Angiographically defined primary angiitis of the CNS: Is it really benign? Neurology 51: 183–188

    Article  PubMed  CAS  Google Scholar 

  43. Yazici H, Yurdakul S, Hamuryudan V. Behcet disease. Curr Opin Rheumatol 2001; 13: 18–22

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Klinik, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg

    Dr B. Storch-Hagenlocher

  2. Neurologische Klinik, Alfried-Krupp-Krankenhaus, Alfried-Krupp-Str. 21, 45131, Essen

    Prof. Dr. P. Berlit

Authors
  1. Dr B. Storch-Hagenlocher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. P. Berlit
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurologische Klinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen

    Stefan Schwab  & Peter Schellinger  & 

  2. Klinik für Anästhesiologie, Klinikum der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz

    Christian Werner

  3. Neurochirurgische Klinik, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg

    Andreas Unterberg  & Werner Hacke  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Storch-Hagenlocher, B., Berlit, P. (2008). Autoimmunerkrankungen. In: Schwab, S., Schellinger, P., Werner, C., Unterberg, A., Hacke, W. (eds) NeuroIntensiv. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68317-9_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68317-9_36

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-23051-9

  • Online ISBN: 978-3-540-68317-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation